Michael R. Dougherty - 01 Jul 2022 Form 4 Insider Report for IDERA PHARMACEUTICALS, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 01 Jul 2022
Net transaction value: +$21,938
SEC form: 4
Accepted by SEC: 06 Jul 2022, 16:30:36 UTC
Prior SEC filing: 27 Jun 2022
Next SEC filing: 05 Oct 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael R. Dougherty

Filing notes and source

Key filing fact

Michael R. Dougherty filed Form 4 for IDERA PHARMACEUTICALS, INC. on 06 Jul 2022.

Key facts

This page summarizes Michael R. Dougherty's Form 4 filing for IDERA PHARMACEUTICALS, INC..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 06 Jul 2022, 16:30.

Change

Previous filing in this sequence was filed on 27 Jun 2022.
Current net transaction value: +$21,938.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDRA transaction

Common Stock

Award

Transaction value: $21,938
Shares: +50,086
Change %: +21%
Price: $0.4380
Shares after: 283,116
Date: 01 Jul 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock was issued to the reporting person pursuant to his election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees.